213 related articles for article (PubMed ID: 8161332)
1. Role of immunoperoxidase staining in serous effusions.
Sarker AB; Hoshida Y; Nose S
Bangladesh Med Res Counc Bull; 1993 Aug; 19(2):33-8. PubMed ID: 8161332
[TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
3. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
Marsan C; Gaulier A; Sabatier P; Garcia R
Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
[TBL] [Abstract][Full Text] [Related]
4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
5. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
6. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
[TBL] [Abstract][Full Text] [Related]
7. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
Daste G; Gioanni J; Lauque D; Kremps M; Mazeau C; Paquis P; Schneider M
Arch Anat Cytol Pathol; 1997; 45(4):185-91. PubMed ID: 9406475
[TBL] [Abstract][Full Text] [Related]
8. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
Pinto MM
Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy.
Kahn HJ; Hanna W; Yeger H; Baumal R
Am J Pathol; 1982 Nov; 109(2):206-14. PubMed ID: 6182803
[TBL] [Abstract][Full Text] [Related]
11. Cytological study of serous effusions with the aid of tumour markers.
Ray K; Mittal S; Gupta H; Jain M
J Indian Med Assoc; 1999 Jan; 97(1):11-2, 19. PubMed ID: 10549179
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
14. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
15. Distribution of silver-stained interphase nucleolar organizer regions as a parameter to distinguish neoplastic from nonneoplastic reactive cells in human effusions.
Derenzini M; Nardi F; Farabegoli F; Ottinetti A; Roncaroli F; Bussolati G
Acta Cytol; 1989; 33(4):491-8. PubMed ID: 2473585
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing benign from malignant pleural effusions by lectin immunocytochemistry.
Rosen-Levin E; Patil JR; Watson CW; Jagirdar J
Acta Cytol; 1989; 33(4):499-504. PubMed ID: 2473586
[TBL] [Abstract][Full Text] [Related]
17. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
Ruitenbeek T; Gouw AS; Poppema S
Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
19. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the cytodiagnosis of serous effusions.
al-Nafussi A; Carder PJ
Cytopathology; 1990; 1(2):119-28. PubMed ID: 1714782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]